Prostate Cancer Clinical Trial
Official title:
LCCC 1636: Using PROMIS as Part of Routine Clinical Care for Racially Diverse Prostate and Bladder Cancer Patients
In this pilot study, a total of 80 patients with prostate or bladder cancer (40 black, 40 white) will complete 3 patient-reported outcome (PRO) surveys: baseline (pre-treatment), during treatment, and after treatment. The overall goal of this study is to assess whether collecting patient-reported data is feasible as part of clinical care of cancer patients, and whether these data are useful for clinicians and patients. Among these 80 patients, those who agree will also undergo a semi-structured interview to assess value of HRQOL assessment at the end of the study. Of specific interest is an evaluation of whether feasibility and perceived value differ between black and white participants.
Cancer treatments, including surgery, radiotherapy and chemotherapy, are often linked to
acute and late side effects. Historically, these effects were assessed by physicians and
scored using standardized scales such as the Common Terminology Criteria for Adverse Events
(CTCAE). Thorough and accurate assessment of symptoms facilitates timely and patient-centered
symptom management.
Multiple studies have demonstrated that PROs more accurately capture patient symptoms than
physician assessment. In a prospective trial, Falchook et al. investigated patient vs.
physician report of symptoms in head and neck cancer patients undergoing radiotherapy (N=44).
Patients and physicians separately completed weekly symptom assessments during treatment and
once during follow-up. Patients tended to report more severe symptoms than physicians. For
example, in week six, physicians rated 86% of patients' fatigue as non-existent or mild while
86% of patients rated their own fatigue as moderate to very severe. In a larger study
conducted at Memorial Sloan-Kettering Cancer Center of 163 lung cancer patients undergoing
chemotherapy, Basch et al. similarly examined patient vs. physician report of symptoms over
one year. Compared to patients, physicians reported less severe and lower rates of fatigue,
nausea, and pain and higher functional status.
Findings from these prior studies are consistent with evidence from a recent systematic
review, which concluded that PRO data were essential for the evaluation of symptoms in cancer
survivors. Many researchers have hypothesized the reasons behind this discrepancy in
physician/patient ratings of symptoms, including poor communication, inadequate physician
time spent per patient, and patients' underreporting of symptoms to physicians. Thus,
incorporation of PRO data into routine clinical care can facilitate better detection and
management of cancer and treatment-related effects.
Therefore, the goal of this pilot study is to move PRO data collection from a purely research
exercise into using this as a tool to improve care for cancer patients. This pilot study will
assess the feasibility of collecting PRO data as part of clinical care, and assess its
"value" from the patient and physician perspectives. The investigators will recruit 80
patients with prostate or bladder cancers from the UNC Genitourinary Oncology clinics
(including Urology and Radiation Oncology). PRO data that is most relevant to this patient
population will be collected, including: gastrointestinal, urinary, sexual function,
anxiety/depression, and sleep.
Further, given longstanding racial disparities in symptom experiences (e.g., symptom
assessment, severity, frequency) among cancer patients and limited evidence of effective
strategies for mitigating such inequities, this pilot study will also examine Black-White
differences in terms of the feasibility and perceived value of sharing of patient-reported
data to improve communication and decision-making.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Active, not recruiting |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |